CN112021483A - 一种泡腾凝胶干粉制剂及其制备方法 - Google Patents
一种泡腾凝胶干粉制剂及其制备方法 Download PDFInfo
- Publication number
- CN112021483A CN112021483A CN202010956496.5A CN202010956496A CN112021483A CN 112021483 A CN112021483 A CN 112021483A CN 202010956496 A CN202010956496 A CN 202010956496A CN 112021483 A CN112021483 A CN 112021483A
- Authority
- CN
- China
- Prior art keywords
- dry powder
- gel
- effervescent
- gel dry
- quick
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 59
- 239000000843 powder Substances 0.000 title claims description 56
- 239000004088 foaming agent Substances 0.000 claims abstract description 38
- 239000000203 mixture Substances 0.000 claims abstract description 36
- 238000009472 formulation Methods 0.000 claims abstract description 24
- 239000004480 active ingredient Substances 0.000 claims abstract description 21
- 239000003814 drug Substances 0.000 claims abstract description 8
- 239000004615 ingredient Substances 0.000 claims abstract description 7
- 229940079593 drug Drugs 0.000 claims abstract description 6
- 239000007863 gel particle Substances 0.000 claims description 35
- 239000002245 particle Substances 0.000 claims description 35
- 239000003086 colorant Substances 0.000 claims description 22
- 239000000796 flavoring agent Substances 0.000 claims description 22
- 235000013355 food flavoring agent Nutrition 0.000 claims description 22
- 239000006068 taste-masking agent Substances 0.000 claims description 22
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 18
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 12
- 229920002125 Sokalan® Polymers 0.000 claims description 12
- 229960001631 carbomer Drugs 0.000 claims description 12
- 239000008187 granular material Substances 0.000 claims description 9
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 9
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 9
- 229940093429 polyethylene glycol 6000 Drugs 0.000 claims description 7
- 239000000126 substance Substances 0.000 claims description 6
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims description 4
- 239000000945 filler Substances 0.000 claims description 4
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 3
- 229920000148 Polycarbophil calcium Polymers 0.000 claims description 3
- 229960000502 poloxamer Drugs 0.000 claims description 3
- 229920001983 poloxamer Polymers 0.000 claims description 3
- 229950005134 polycarbophil Drugs 0.000 claims description 3
- YQSHYGCCYVPRDI-UHFFFAOYSA-N (4-propan-2-ylphenyl)methanamine Chemical compound CC(C)C1=CC=C(CN)C=C1 YQSHYGCCYVPRDI-UHFFFAOYSA-N 0.000 claims description 2
- 241000193755 Bacillus cereus Species 0.000 claims description 2
- 241000194108 Bacillus licheniformis Species 0.000 claims description 2
- 241000186000 Bifidobacterium Species 0.000 claims description 2
- 229930186147 Cephalosporin Natural products 0.000 claims description 2
- 241000193171 Clostridium butyricum Species 0.000 claims description 2
- 241000194033 Enterococcus Species 0.000 claims description 2
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims description 2
- 240000001046 Lactobacillus acidophilus Species 0.000 claims description 2
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims description 2
- 241000218588 Lactobacillus rhamnosus Species 0.000 claims description 2
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 claims description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical group [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims description 2
- 229940124587 cephalosporin Drugs 0.000 claims description 2
- 125000001271 cephalosporin group Chemical group 0.000 claims description 2
- 229960003782 dextromethorphan hydrobromide Drugs 0.000 claims description 2
- 229960001680 ibuprofen Drugs 0.000 claims description 2
- 229940039695 lactobacillus acidophilus Drugs 0.000 claims description 2
- 239000003120 macrolide antibiotic agent Substances 0.000 claims description 2
- VSZGPKBBMSAYNT-RRFJBIMHSA-N oseltamivir Chemical compound CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 VSZGPKBBMSAYNT-RRFJBIMHSA-N 0.000 claims description 2
- 229960003752 oseltamivir Drugs 0.000 claims description 2
- 229960005489 paracetamol Drugs 0.000 claims description 2
- 229960000329 ribavirin Drugs 0.000 claims description 2
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 claims description 2
- 229960002181 saccharomyces boulardii Drugs 0.000 claims description 2
- 239000011782 vitamin Substances 0.000 claims description 2
- 229940088594 vitamin Drugs 0.000 claims description 2
- 229930003231 vitamin Natural products 0.000 claims description 2
- 235000013343 vitamin Nutrition 0.000 claims description 2
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims 5
- 229920001223 polyethylene glycol Polymers 0.000 claims 5
- PMVSDNDAUGGCCE-TYYBGVCCSA-L Ferrous fumarate Chemical compound [Fe+2].[O-]C(=O)\C=C\C([O-])=O PMVSDNDAUGGCCE-TYYBGVCCSA-L 0.000 claims 1
- 240000006024 Lactobacillus plantarum Species 0.000 claims 1
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims 1
- 239000004353 Polyethylene glycol 8000 Substances 0.000 claims 1
- 229940031663 carbomer-974p Drugs 0.000 claims 1
- 235000002332 ferrous fumarate Nutrition 0.000 claims 1
- 229960000225 ferrous fumarate Drugs 0.000 claims 1
- 239000011773 ferrous fumarate Substances 0.000 claims 1
- 229940072205 lactobacillus plantarum Drugs 0.000 claims 1
- 239000011236 particulate material Substances 0.000 claims 1
- 229940057838 polyethylene glycol 4000 Drugs 0.000 claims 1
- 229940085678 polyethylene glycol 8000 Drugs 0.000 claims 1
- 235000019446 polyethylene glycol 8000 Nutrition 0.000 claims 1
- 235000015497 potassium bicarbonate Nutrition 0.000 claims 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 claims 1
- 239000011736 potassium bicarbonate Substances 0.000 claims 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 claims 1
- 239000000499 gel Substances 0.000 abstract description 69
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 13
- 235000013305 food Nutrition 0.000 abstract description 5
- 230000008961 swelling Effects 0.000 abstract description 5
- 239000000017 hydrogel Substances 0.000 abstract 1
- 239000003349 gelling agent Substances 0.000 description 21
- 150000001875 compounds Chemical class 0.000 description 11
- 230000009747 swallowing Effects 0.000 description 7
- QYIYFLOTGYLRGG-GPCCPHFNSA-N cefaclor Chemical compound C1([C@H](C(=O)N[C@@H]2C(N3C(=C(Cl)CS[C@@H]32)C(O)=O)=O)N)=CC=CC=C1 QYIYFLOTGYLRGG-GPCCPHFNSA-N 0.000 description 6
- 229960005361 cefaclor Drugs 0.000 description 6
- 208000019505 Deglutition disease Diseases 0.000 description 5
- 230000011514 reflex Effects 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 4
- 230000004064 dysfunction Effects 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 241000723418 Carya Species 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 210000003437 trachea Anatomy 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 239000004964 aerogel Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 235000014347 soups Nutrition 0.000 description 2
- 206010003497 Asphyxia Diseases 0.000 description 1
- 239000008118 PEG 6000 Substances 0.000 description 1
- 206010035669 Pneumonia aspiration Diseases 0.000 description 1
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- 201000009807 aspiration pneumonia Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 229960002598 fumaric acid Drugs 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000011229 interlayer Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000021056 liquid food Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/40—Effervescence-generating compositions
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/14—Yeasts or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0007—Effervescent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/113—Acidophilus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/175—Rhamnosus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Microbiology (AREA)
- Physiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明涉及一种新型口服制剂平台:泡腾凝胶(Effervescent gel EG)剂。其主要由速膨凝胶剂,致泡剂,活性成分,辅助成分所组成。泡腾凝胶剂与适量的水剂,或水溶液混合,可快速(一般少于30秒)膨胀并形成均匀多泡水凝胶,该剂型具有成胶快,配制方便,凝胶均一,口感顺滑及粘稠度可调的特点,尤其适用于小儿,老人和具有吞咽反射功能障碍的患者服用。口服泡腾凝胶剂具有方便,安全和极佳的口感,明显增加儿童患者的顺应性,可应用于药品,食品及保健品等领域。
Description
技术领域
本发明涉及一种用于药物、食品及保健品的口服制剂,具体涉及一种泡腾凝胶干粉制剂及其制备方法。
背景技术
口服制剂一般包括片剂、胶囊剂、混悬剂、颗粒剂、溶液剂、糖浆剂和凝胶剂等。对于婴幼儿及一些具有特殊吞咽反射功能障碍的患者,由于他(她)们因为年龄,身体或患病原因,吞咽反射出现障碍,在吞咽过程中,很容易出现误吸,将液体或固体口服物吸入气管,造成吸入性肺炎或窒息甚至死亡。因此,最适合他(她)们的口服剂型是具有一定黏稠度,且黏稠度可调节的凝胶剂。一定的黏度可以使凝胶剂黏附于口腔和咽部粘膜,只能通过吞咽进入食管,而防止误吸进入气管;一定的稠度可以使凝胶剂形成较大块状,降低其流动性,既易于吞咽,又能防止口服物质因体位重力原因流入气管。
根据患者吞咽反射功能障碍的严重程度不同,饮食习惯的不同,患者需要不同黏稠度的凝胶剂去满足各种不同的需求。目前市场上的凝胶剂很少,黏稠度是固定的,不可调节,制备过程中一般需要加入防腐剂,且需低温保存。
由于目前市场凝胶剂的缺陷,远远不能满足婴幼儿及一些具有特殊吞咽反射功能障碍的患者的需求,且目前的凝胶剂不是新鲜配制,口感较差,也不容易获得广泛应用。
发明内容
本发明所要解决的技术问题是提供一种具有黏稠度可调的新型口服泡腾凝胶制剂。可以满足婴幼儿及一些具有特殊吞咽反射功能障碍的患者对口服药品及食品的需求。
为实现上述技术效果,本发明提供一种泡腾凝胶干粉制剂,所述泡腾凝胶干粉制剂包含药物成分或活性成分之一、速膨凝胶颗粒、致泡剂和辅助填料;所述速膨凝胶颗粒由卡波姆或聚卡波非均匀粘附聚于乙二醇颗粒表面构成;所述泡腾凝胶干粉制剂中速膨凝胶颗粒的重量百分比为5%~15%;且所述致泡剂占所述泡腾凝胶干粉制剂的重量百分比不小于所述速膨凝胶颗粒占所述泡腾凝胶干粉制剂的重量百分比的1/5。
在一个实施例中,所述药物成分是头孢类药物、大环内酯类药物、利巴韦林、奥司他韦、富马酸亚、布洛芬、对乙酰氨基酚、维生素类药物、氢溴酸右美沙芬或中成药颗粒。
在一个实施例中,所述药物成分占所述泡腾凝胶干粉制剂的重量百分比为1%~50%。
在一个实施例中,所述活性成分为嗜酸乳杆菌、AKK、双歧杆菌、鼠李糖乳杆菌、酪酸梭菌、布拉酵母菌、肠球菌、地衣芽孢杆菌或蜡样芽孢杆菌。
在一个实施例中,所述速膨凝胶颗粒卡为波姆971P均匀粘附于聚乙二醇6000蜡粒表面形成较致密的颗粒物质。
在一个实施例中,所述致泡剂采用碳酸氢钠,所述致泡剂占所述泡腾凝胶干粉制剂的重量百分比为1%~5%。
在一个实施例中,所述辅助填料包括矫味剂、掩味剂和着色剂,所述矫味剂占所述泡腾凝胶干粉制剂的重量百分比为40%~90%;所述掩味剂占所述泡腾凝胶干粉制剂的重量百分比为0%~10%;所述着色剂占所述泡腾凝胶干粉制剂的重量百分比为0%~6%。
本发明的另一个方面还在于提供一种泡腾凝胶干粉预调剂,所述泡腾凝胶干粉预调剂用于与其他颗粒制剂混合配置成泡腾凝胶制剂,所述所述泡腾凝胶干粉预调剂包括速膨凝胶颗粒和致泡剂,且所述致泡剂占所述泡腾凝胶干粉预调剂的重量百分比不小于所述速膨凝胶颗粒占所述泡腾凝胶干粉预调剂的重量百分比的1/5;所述速膨凝胶颗粒卡为波姆971P均匀粘附于聚乙二醇6000蜡粒表面形成较致密的颗粒物质;所述致泡剂采用碳酸氢钠。
本发明中所使用的所述速膨凝胶颗粒卡为波姆971P均匀粘附于聚乙二醇6000蜡粒表面形成较致密的颗粒物质,其平均粒径为50-250μm,由于卡波姆聚或卡波非自身所带的大量羧基,其在碳酸氢钠溶液中会与碳酸氢钠发生反应生产水和二氧化碳气体,同时卡波姆在碱性溶液中会变得浓稠形成凝胶。因此本发明的速膨凝胶颗粒和致泡剂混合物在与水混合后能够快速的形成气泡凝胶,同时把药物或活性物质裹挟在内。
本发明的发明点在于如下几个方面:
1.本发明提出了使用速膨凝胶颗粒与致泡剂相配合的方法生产含泡凝胶,从而产生了一种新型口服制剂类型—泡腾凝胶剂,改善了现有技术中凝胶制剂的口感和顺滑度。
2.本发明中进一步通过实验确定了速膨凝胶颗粒的使用含量,以获得最佳的凝胶制剂的口感和顺滑度。同时确定了速膨凝胶颗粒与致泡剂之间的使用比例。
附图说明
附图用来提供对本发明的进一步理解,并且构成说明书的一部分,与本发明的实施例共同用于解释本发明,并不构成对本发明的限制。在附图中:
图1为本发明中所使用的速膨凝胶颗粒的粒径分布示意图。
图2为本发明所生成的气泡凝胶与现有技术中的希克劳干混悬制剂在头孢克洛成分上的溶出度对比示意图。
具体实施方式
以下结合附图对本发明实施方式做进一步阐述。
实施例1
以上所述,仅为本发明的具体实施案例,本发明的保护范围并不局限于此,任何熟悉本技术的技术人员在本发明所述的技术规范内,对本发明的修改或替换,都应在本发明的保护范围之内。
本实施例中首先制备速膨凝胶剂颗粒,所述速膨凝胶剂颗粒的制作过程如下:
将500克卡波姆971P置于一湿法制粒机锅内,通过锅的夹层用95度水浴加热卡波姆971P。在15转/分钟的搅拌桨搅拌下,卡波姆971P将逐渐升温,当温度达到85-90度时,将聚乙二醇6000(PEG6000)颗粒320克缓慢倒入湿法制粒机锅内,然后将搅拌桨速度提高为30转/分钟,保持95度水浴加热。大约2-10分钟后,卡波姆将均匀粘附于聚乙二醇6000蜡粒表面,形成较致密的颗粒。制粒完成后将物料倒出,稍冷却后过20目筛,即速膨凝胶剂颗粒为制备完成。速膨凝胶剂颗粒平均粒径约为150μm。速膨凝胶剂颗粒的粒径分布见图1。
取上述制备完成的速膨凝胶颗粒10g、药物活性成分6g、致泡剂2g、矫味剂84g、掩味剂3g、着色剂1g。充分混合制成100g本实施例的泡腾凝胶干粉制剂。本实施例中所使用的药物活性成分、致泡剂、矫味剂、掩味剂和着色剂的具体使用的化合物如下表1所示。
表1
成分 | 具体化合物 |
药物活性成分 | 头孢克洛 |
致泡剂 | 碳酸氢钠 |
矫味剂 | 蔗糖粉 |
掩味剂 | 果味香精 |
着色剂 | 落日黄 |
实施例2
本实施例中首先制备速膨凝胶剂颗粒,所述速膨凝胶剂颗粒的制作过程与实施例1中的所记载的速膨凝胶剂颗粒制备过程完全一致。
取上述制备完成的速膨凝胶颗粒10g、药物活性成分10g、致泡剂3g、矫味剂73g、掩味剂3g、着色剂1g。充分混合制成100g本实施例的泡腾凝胶干粉制剂。本实施例中所使用的药物活性成分、致泡剂、矫味剂、掩味剂和着色剂的具体使用的化合物如下表2所示。
表2
实施例3
本实施例中首先制备速膨凝胶剂颗粒,所述速膨凝胶剂颗粒的制作过程与实施例1中的所记载的速膨凝胶剂颗粒制备过程完全一致。
取上述制备完成的速膨凝胶颗粒12g、药物活性成分8g、致泡剂4g、矫味剂72g、掩味剂3g、着色剂1g。充分混合制成100g本实施例的泡腾凝胶干粉制剂。本实施例中所使用的药物活性成分、致泡剂、矫味剂、掩味剂和着色剂的具体使用的化合物如下表3所示。
表3
成分 | 具体化合物 |
药物活性成分 | 头孢克洛 |
致泡剂 | 碳酸氢钠 |
矫味剂 | 木糖醇 |
掩味剂 | 果味香精 |
着色剂 | 落日黄 |
实施例4
本实施例中首先制备速膨凝胶剂颗粒,所述速膨凝胶剂颗粒的制作过程与实施例1中的所记载的速膨凝胶剂颗粒制备过程完全一致。
取上述制备完成的速膨凝胶颗粒15g、药物活性成分12g、致泡剂4g、矫味剂58g、掩味剂8g、着色剂1g。充分混合制成100g本实施例的泡腾凝胶干粉制剂。本实施例中所使用的药物活性成分、致泡剂、矫味剂、掩味剂和着色剂的具体使用的化合物如下表4所示。
表4
比较例1
本实施例中首先制备速膨凝胶剂颗粒,所述速膨凝胶剂颗粒的制作过程与实施例1中的所记载的速膨凝胶剂颗粒制备过程完全一致。
取上述制备完成的速膨凝胶颗粒4g、药物活性成分10g、致泡剂2g、矫味剂80g、掩味剂3g、着色剂1g。充分混合制成100g本实施例的泡腾凝胶干粉制剂。本实施例中所使用的药物活性成分、致泡剂、矫味剂、掩味剂和着色剂的具体使用的化合物如下表5所示。
表5
成分 | 具体化合物 |
药物活性成分 | 头孢克洛 |
致泡剂 | 碳酸氢钠 |
矫味剂 | 蔗糖粉 |
掩味剂 | 果味香精 |
着色剂 | 落日黄 |
比较例2
本实施例中首先制备速膨凝胶剂颗粒,所述速膨凝胶剂颗粒的制作过程与实施例1中的所记载的速膨凝胶剂颗粒制备过程完全一致。
取上述制备完成的速膨凝胶颗粒18g、药物活性成分6g、致泡剂8g、矫味剂64g、掩味剂3g、着色剂1g。充分混合制成100g本实施例的泡腾凝胶干粉制剂。本实施例中所使用的药物活性成分、致泡剂、矫味剂、掩味剂和着色剂的具体使用的化合物如下表5所示。
表5
比较例3
本实施例中首先制备速膨凝胶剂颗粒,所述速膨凝胶剂颗粒的制作过程与实施例1中的所记载的速膨凝胶剂颗粒制备过程完全一致。
取上述制备完成的速膨凝胶颗粒13g、药物活性成分6g、致泡剂2g、矫味剂75g、掩味剂3g、着色剂1g。充分混合制成100g本实施例的泡腾凝胶干粉制剂。本实施例中所使用的药物活性成分、致泡剂、矫味剂、掩味剂和着色剂的具体使用的化合物如下表5所示。
表5
成分 | 具体化合物 |
药物活性成分 | 头孢克洛 |
致泡剂 | 碳酸氢钠 |
矫味剂 | 蔗糖粉 |
掩味剂 | 果味香精 |
着色剂 | 落日黄 |
将上述制备完成的泡腾凝胶干粉制取10g剂置于干净容器内,混合均匀后,加入25毫升水,用小汤勺轻轻搅拌约10-20秒钟,泡腾凝胶干粉制剂与水混合后,迅速膨胀,形成均一的泡腾凝胶,上述实施例1-4及比较例1-3所形成的凝胶其口感效果如下表6所示。
表6
具有吞咽障碍的病人其在食用流食时,当食物过稀时容易造成呛咳;当食物过稠时容易引起吞咽困难。同时为了使药物或活性物质充分溶解在水中,所使用的水的用量是存在最低限用量的。根据表6可知,本发明中速膨凝胶颗粒的重量百分比含量需设定在5%~15%之间,从而保证所制备的泡腾凝胶干粉制剂在与水混合后所获得的凝胶具有合适的粘稠度,从而使得吞咽障碍病人能够较为容易的进行口服动作。同时为了避免凝胶中形成絮状结块,致泡剂的重量百分比应大于泡腾凝胶干粉重量百分比的1/5,从而保证泡腾凝胶干粉制剂在与水混合后形成均匀的凝胶制剂,防止絮状结块出现。本发明的气泡凝胶与现有市场中的希克劳干混悬制剂在头孢克洛成分上的溶出度对比结果如图2所示,可以看出本发明的气泡凝胶在药物体外释放上和希克劳干混悬剂类似,30分钟均可达到基本完全释放,没有显著差异。
实施例5
本实施例在于制作一种气泡凝胶干粉预调剂,本实施例中首先制备速膨凝胶剂颗粒,所述速膨凝胶剂颗粒的制作过程与实施例1中的所记载的速膨凝胶剂颗粒制备过程完全一致。
取上述制备完成的速膨凝胶颗粒100g与碳酸氢钠20g充分混合制成120g本实施例的气泡凝胶干粉预调剂。取上述2g气泡凝胶干粉预调剂置于干净容器内,然后加入药物混合均匀后,加入25毫升水,用小汤勺轻轻搅拌约15-20秒钟,泡腾凝胶干粉制剂与水混合后,迅速膨胀,形成均一的泡腾凝胶。混合后所获得的凝胶具有合适的粘稠度,从而使得吞咽障碍病人能够较为容易的进行口服动作。
由上述实施例可知,本发明所提供的气泡凝胶干粉制剂或气泡凝胶干粉预调剂能够实现快速形成适合于使具有吞咽障碍病人较为容易的进行口服的凝胶制剂,本实施例中所体现本发明的发明点主要在两个方面,第一、本发明提出了使用速膨凝胶颗粒与致泡剂相配合的方法生产含泡凝胶的方法,本发明中利用,卡波姆或聚卡波非自身所带的大量羧基,其在碳酸氢钠溶液中会与碳酸氢钠发生反应生产水和二氧化碳气体,从而改善了现有技术中凝胶制剂的口感和顺滑度。第二、本发明中进一步通过实验确定了速膨凝胶颗粒的使用含量以及速膨凝胶颗粒与致泡剂之间的使用比例,以获得最佳的凝胶制剂的口感和顺滑度。
Claims (8)
1.一种泡腾凝胶干粉制剂,其特征在于,所述泡腾凝胶干粉制剂包含药物成分或活性成分之一、速膨凝胶颗粒、致泡剂和辅助填料;所述速膨凝胶颗粒由卡波姆或聚卡波非均匀粘附与聚乙二醇颗粒表面构成;所述泡腾凝胶干粉制剂中速膨凝胶颗粒的重量百分比为5%~15%;且所述致泡剂占所述泡腾凝胶干粉制剂的重量百分比不小于所述速膨凝胶颗粒占所述泡腾凝胶干粉制剂的重量百分比的1/5。
2.根据权利要求1所述的泡腾凝胶干粉制剂,其特征在于,所述药物成分是头孢类药物、大环内酯类药物、利巴韦林、奥司他韦、富马酸亚铁、布洛芬、对乙酰氨基酚、维生素类药物、氢溴酸右美沙芬或中成药颗粒。
3.根据权利要求1所述的泡腾凝胶干粉制剂,其特征在于,所述活性成分为植物乳杆菌、嗜酸乳杆菌、AKK、双歧杆菌、鼠李糖乳杆菌、酪酸梭菌、布拉酵母菌、肠球菌、地衣芽孢杆菌或蜡样芽孢杆菌。
4.根据权利要求1所述的泡腾凝胶干粉制剂,其特征在于,所述药物成分占所述泡腾凝胶干粉制剂的重量百分比为1%~50%。
5.根据权利要求1所述的泡腾凝胶干粉制剂,其特征在于,所述速膨凝胶颗粒为卡波姆971P,卡波姆974P,卡波姆934P或聚卡波非均匀粘附于聚乙二醇蜡粒表面,形成较致密的颗粒物质,所述聚乙二醇为聚乙二醇4000,聚乙二醇6000,聚乙二醇8000,聚乙二醇10000或聚乙二醇12000.
6.根据权利要求1所述的泡腾凝胶干粉制剂,其特征在于,所述致泡剂采用碳酸氢钠,所述致泡剂占所述泡腾凝胶干粉制剂的重量百分比为1%~5%。
7.根据权利要求1所述的泡腾凝胶干粉制剂,其特征在于,所述辅助填料包括矫味剂、掩味剂和着色剂,所述矫味剂占所述泡腾凝胶干粉制剂的重量百分比为40%~90%;所述掩味剂占所述泡腾凝胶干粉制剂的重量百分比为0%~10%;所述着色剂占所述泡腾凝胶干粉制剂的重量百分比为0%~6%。
8.一种泡腾凝胶干粉预调剂,其特征在于,所述泡腾凝胶干粉预调剂用于与其他颗粒制剂混合配置成泡腾凝胶制剂,所述所述泡腾凝胶干粉预调剂包括速膨凝胶颗粒和致泡剂,且所述致泡剂占所述泡腾凝胶干粉预调剂的重量百分比不小于所述速膨凝胶颗粒占所述泡腾凝胶干粉预调剂的重量百分比的1/5;所述速膨凝胶颗粒卡为波姆971P均匀粘附于聚乙二醇6000蜡粒表面形成较致密的颗粒物质;所述致泡剂采用碳酸氢钠或碳酸氢钾。
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010956496.5A CN112021483B (zh) | 2020-09-11 | 2020-09-11 | 一种泡腾凝胶干粉制剂及其制备方法 |
US18/007,043 US20230277440A1 (en) | 2020-09-11 | 2021-08-03 | Effervescent gel dry powder formulation and preparation method thereof |
PCT/CN2021/110337 WO2022052672A1 (zh) | 2020-09-11 | 2021-08-03 | 一种泡腾凝胶干粉制剂及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010956496.5A CN112021483B (zh) | 2020-09-11 | 2020-09-11 | 一种泡腾凝胶干粉制剂及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112021483A true CN112021483A (zh) | 2020-12-04 |
CN112021483B CN112021483B (zh) | 2022-07-15 |
Family
ID=73588955
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010956496.5A Active CN112021483B (zh) | 2020-09-11 | 2020-09-11 | 一种泡腾凝胶干粉制剂及其制备方法 |
Country Status (3)
Country | Link |
---|---|
US (1) | US20230277440A1 (zh) |
CN (1) | CN112021483B (zh) |
WO (1) | WO2022052672A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022052672A1 (zh) * | 2020-09-11 | 2022-03-17 | 宁波聚焦生物医药科技股份有限公司 | 一种泡腾凝胶干粉制剂及其制备方法 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6375986B1 (en) * | 2000-09-21 | 2002-04-23 | Elan Pharma International Ltd. | Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate |
CN1706389A (zh) * | 2005-05-26 | 2005-12-14 | 济南平志医药科技有限公司 | 头孢地尼泡腾制剂及其制备方法 |
JP2006306639A (ja) * | 2005-04-26 | 2006-11-09 | Equos Research Co Ltd | カーボンエアロゲル及びその製造方法 |
CN1964699A (zh) * | 2004-06-07 | 2007-05-16 | 株式会社吴羽 | 干燥形态经口摄取用组合物和用时调制型凝胶状经口摄取用组合物 |
CN101856321A (zh) * | 2009-04-10 | 2010-10-13 | 王洪光 | 口服干凝胶剂 |
CN103721264A (zh) * | 2014-01-12 | 2014-04-16 | 苏州麦克威尔生物医药科技有限公司 | 一种用于助吞咽口服固体药物制剂的凝胶剂 |
CN105708809A (zh) * | 2015-05-09 | 2016-06-29 | 张秋野 | 一种控缓释剂药用辅料的热熔融制粒方法 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102697751A (zh) * | 2012-05-30 | 2012-10-03 | 河南牧翔动物药业有限公司 | 一种畜禽专用恩诺沙星泡腾分散片及其制备方法 |
CN104224719A (zh) * | 2013-06-06 | 2014-12-24 | 南京亿华药业有限公司 | 一种头孢地尼干混悬剂及其制备方法 |
CN112021483B (zh) * | 2020-09-11 | 2022-07-15 | 宁波聚焦生物医药科技股份有限公司 | 一种泡腾凝胶干粉制剂及其制备方法 |
-
2020
- 2020-09-11 CN CN202010956496.5A patent/CN112021483B/zh active Active
-
2021
- 2021-08-03 WO PCT/CN2021/110337 patent/WO2022052672A1/zh active Application Filing
- 2021-08-03 US US18/007,043 patent/US20230277440A1/en active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6375986B1 (en) * | 2000-09-21 | 2002-04-23 | Elan Pharma International Ltd. | Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate |
CN1964699A (zh) * | 2004-06-07 | 2007-05-16 | 株式会社吴羽 | 干燥形态经口摄取用组合物和用时调制型凝胶状经口摄取用组合物 |
JP2006306639A (ja) * | 2005-04-26 | 2006-11-09 | Equos Research Co Ltd | カーボンエアロゲル及びその製造方法 |
CN1706389A (zh) * | 2005-05-26 | 2005-12-14 | 济南平志医药科技有限公司 | 头孢地尼泡腾制剂及其制备方法 |
CN101856321A (zh) * | 2009-04-10 | 2010-10-13 | 王洪光 | 口服干凝胶剂 |
CN103721264A (zh) * | 2014-01-12 | 2014-04-16 | 苏州麦克威尔生物医药科技有限公司 | 一种用于助吞咽口服固体药物制剂的凝胶剂 |
CN105708809A (zh) * | 2015-05-09 | 2016-06-29 | 张秋野 | 一种控缓释剂药用辅料的热熔融制粒方法 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022052672A1 (zh) * | 2020-09-11 | 2022-03-17 | 宁波聚焦生物医药科技股份有限公司 | 一种泡腾凝胶干粉制剂及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
WO2022052672A1 (zh) | 2022-03-17 |
CN112021483B (zh) | 2022-07-15 |
US20230277440A1 (en) | 2023-09-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3122141B2 (ja) | 口腔内溶解型圧縮成型物及びその製造法 | |
EP0804170B1 (en) | Method for making freeze dried drug dosage forms | |
US6214386B1 (en) | Prompt-release oral pharmaceutical compositions for extemporaneous suspensions | |
KR0146960B1 (ko) | 마이크로-입자 또는 나노-입자로 구성된 신규한 고체 다공성 단위체 및 그것의 제조방법 | |
EP1674083B1 (en) | Tablet quickly disintegrating in oral cavity | |
US8900629B2 (en) | Rapidly dissolving pharmaceutical compositions comprising pullulan | |
CN1275335A (zh) | 稳定的泡沫组合物 | |
WO1993015724A1 (en) | Fast soluble tablet | |
JP2000516222A (ja) | 嚥下が容易な経口医薬組成物 | |
JP2000264836A (ja) | 口腔内崩壊型錠剤およびその製造法 | |
JP2002535269A (ja) | 粘膜分配用組成物と方法 | |
JPS6250445B2 (zh) | ||
JP2007537169A (ja) | ジェランガムを含む膨張可能な投与形態 | |
JPS63290822A (ja) | コレスティラミン組成物およびその製法 | |
PT101139B (pt) | Artigos medicamentosos para administracao conformados e porosos e processos para a sua preparacao | |
CA2363592A1 (en) | Oral drug delivery system | |
CN113507923B (zh) | 在线混合期间混悬液的曝气最小化 | |
JPH1133084A (ja) | 口腔内溶解型錠剤およびその製造方法 | |
EP0862421B1 (en) | Prompt-release pharmaceutical compositions | |
CN112021483B (zh) | 一种泡腾凝胶干粉制剂及其制备方法 | |
CN104968335A (zh) | 具有改善的溶解度的新型快速溶解颗粒制剂 | |
JPH1135451A (ja) | 口腔内溶解型錠剤およびその製造方法 | |
CN112402383A (zh) | 一种利培酮冻干片的制备方法及其产品 | |
JP2002255796A (ja) | 口腔内速崩壊型錠剤及びその製造方法 | |
Kállai-Szabó et al. | Microparticles and multi-unit systems for advanced drug delivery |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |